Explain this page
Arphra AIPlain-English read on Pasithea Therapeutics Corp.’s valuation06-10today
- Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial1d
- Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conference2d
- Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conference2d
- Pasithea Therapeutics (KTTA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now7d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $3.00 (+497.25%)
Candlestick · 1Y
Open in chart workstation →KTTA
0.56-33.74%H 0.90L 0.54MA50 0.75MA200 —Avg vol 378K
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.51% | -17.44% | -35.61% | -41.27% | -55.94% | -61.06% | -37.13% | -94.85% | -99.29% | -99.29% | -99.29% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$0.55
63 sh
Bid
$0.48
200 sh
Ask
$0.55
15 sh
Spread
$0.065
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Sector & industry today
LiveSectors
- Utilities+3.33%
- Financial Services+0.02%
- Industrials-0.12%
- Healthcare-0.72%
- Energy-0.94%
- Technology-0.95%
- Consumer Defensive-1.52%
- Basic Materials-1.60%
- Consumer Cyclical-1.74%
- Communication Services-1.79%
- Real Estate-2.19%
Top industries (issuer's industry highlighted)
- Biotechnology+1.24%
- Auto - Dealerships-6.22%
- Trucking-5.25%
- Renewable Utilities+5.11%
- Oil & Gas Energy-4.86%
- Consulting Services-4.82%
- Financial - Mortgages-4.15%
- REIT - Office-3.71%
- Software - Application-3.50%
- Medical - Healthcare Information Services-3.48%
- Grocery Stores-3.45%
- Discount Stores-3.44%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trialglobenewswire.com·Jun 16, 2026
- Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conferenceglobenewswire.com·Jun 15, 2026
- Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conferenceglobenewswire.com·Jun 15, 2026
- Pasithea Therapeutics (KTTA) Could Find a Support Soon, Here's Why You Should Buy the Stock Nowzacks.com·Jun 10, 2026
- Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officerglobenewswire.com·May 04, 2026
- Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officerglobenewswire.com·May 04, 2026
- Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officerglobenewswire.com·May 04, 2026
Peers
No peer list available for KTTA.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|